HENDERSON, Nev., April 23,
2024 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company, has announced that its Nu.Q® Vet Cancer Test is now
available in-clinic to veterinarians across the U.S and
Europe through Antech, a leading
veterinary diagnostics company.
Antech's in-clinic version of the Nu.Q® Canine Cancer
Test operates on the Element i+® Analyzer, providing
veterinarians with a rapid, accurate and cost-effective cancer
screening tool for high-risk breeds and older dogs, at the patient
side, with results in about six minutes.
Dr Tom Butera, Chief Executive
Officer of Volition Veterinary Diagnostics Development LLC, said:
"Through this collaboration, our groundbreaking Nu.Q® technology is
now available to veterinarians across the U.S. and Europe, enabling vital canine cancer screening
and providing in-clinic results within minutes. By incorporating
the Nu.Q® Canine Cancer Test into annual checkups or regular senior
wellness exams, veterinarians can detect cancer¹ earlier and help
pet owners make timely, informed decisions about cancer care."
Dr Butera added:
"Antech's rollout of the Nu.Q® Canine Cancer Test marks a huge
step forward for Volition as we seek to fulfil our mission of
ensuring our epigenetic technology is accessible and affordable
worldwide, to detect and monitor disease earlier and improve
outcomes."
Volition's original license and supply agreement was between
Belgian Volition SRL and Heska, an Antech company, part of Mars
Science & Diagnostics.
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including some cancers and diseases associated with
NETosis such as sepsis. For more information about Volition's
technology go to: www.volition.com
Notes:
[1] Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et
al. Evaluation of plasma nucleosome concentrations in dogs
with a variety of common cancers and in healthy dogs. BMC
Vet Res 18, 329
(2022). https://doi.org/10.1186/s12917-022-03429-8
- According to The Veterinary Cancer Society, one in four
dogs will be diagnosed with cancer, and it's the leading cause of
death in pets who are beyond middle age.
- Approximately 190 million dogs in the U.S. (source) and
Europe (source)
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, as well as
disease and treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's and Antech's website addresses
are not incorporated by reference into this document and should not
be considered part of this document. Such website addresses
are included in this document as inactive textual references
only.
About Mars Science & Diagnostics and
Antech
Mars Science & Diagnostics is a division of Mars
Petcare, a diverse business dedicated to one purpose: A BETTER
WORLD FOR PETS™. Science & Diagnostics brings together the
power of leading pet health science with expertise across
diagnostics, data, and technology to improve outcomes in pet
health. Our veterinary diagnostics business Antech spans
in-house diagnostic laboratory instruments and consumables,
including rapid assay diagnostic products and digital cytology
services; local and cloud-based data services; practice information
management software and related software and support; 90+ reference
laboratories around the globe; veterinary imaging and technology;
education; and board-certified specialist support services. Our
at-home diagnostics offering includes Wisdom Panel™ DNA test
products, the world's most accurate pet DNA test. For 60 years,
our Waltham Petcare Science Institute has been advancing
science to better understand pet health.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Geraldine Varoqui, Antech, geraldine.varoqui@effem.com
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's estimated market
opportunity, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, and Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases. Volition's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties, including, without limitation,
results of studies testing the efficacy of its tests. For instance,
if Volition fails to develop and commercialize diagnostic,
prognostic or disease monitoring products, it may be unable to
execute its plan of operations. Other risks and uncertainties
include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products; a
failure by the marketplace to accept the products in Volition's
development pipeline or any other diagnostic, prognostic or disease
monitoring products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Photo -
https://mma.prnewswire.com/media/2394696/Antech_US_Europe_Element_i.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuq-vet-cancer-test-launched-in-clinic-in-us-and-europe-through-antech-302124578.html
SOURCE VolitionRx Limited